Journal: Clinical Cancer Research

Article Title: Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers

doi: 10.1158/1078-0432.CCR-23-3689

Figure Lengend Snippet: Common mutations in p53abn endometrial tumors. OncoPlot for the top 20 most commonly mutated genes assessed using targeted panel sequencing. The percentage of the cohort with alterations is shown to the right of the bar plot. Tracks for histotypes, tumor stage, 3-year progression-free survival (PFS; with an event being recurrence or death due to disease), and HER2 IHC (defined as: 0, negative; 1, weak; 2, moderate; and 3, strong staining intensity) are shown above. Absolute copy-number tracks for CCNE1 and ERBB2 are defined as: loss (1.5 copies > x), normal (1.5 copies ≤ x < 2.5 copies), gain (2.5 copies ≤ x < 4.5 copies), amplification (4.5 copies ≤ x < 8.5 copies), and high amplification (8.5 copies ≤ x). Ploidy track is shown directly above the mutation plot.

Article Snippet: HER2 IHC was performed on whole sections using the 4B5 rabbit monoclonal anti-HER2 Ab from Roche Ventana.

Techniques: Sequencing, Staining, Amplification, Mutagenesis

Journal: Clinical Cancer Research

Article Title: Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers

doi: 10.1158/1078-0432.CCR-23-3689

Figure Lengend Snippet: p53abn copy-number signatures. Plot summarizing the relationship between Vancouver signature exposures per sample, targeted panel mutations, copy-number status, and various clinical correlates. Per-sample exposures to each of the 5 Vancouver signatures are visualized. Tracks for specific TP53 mutations, mutation status of the top 5 mutated genes are shown on top, followed by their respective copy-number status. Absolute copy-number tracks were classified as follows: loss (1.5 copies > x), normal (1.5 copies ≤ x < 2.5 copies), gain (2.5 copies ≤ x < 4.5 copies), amplification (4.5 copies ≤ x < 8.5 copies), and high amplification (8.5 copies ≤ x). Below the signature exposures are tracks for 3-year PFS, histotype, tumor stage, and HER2 IHC (0, negative; 1, weak; 2, moderate; and 3, strong staining intensity).

Article Snippet: HER2 IHC was performed on whole sections using the 4B5 rabbit monoclonal anti-HER2 Ab from Roche Ventana.

Techniques: Mutagenesis, Amplification, Staining

Journal: Clinical Cancer Research

Article Title: Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers

doi: 10.1158/1078-0432.CCR-23-3689

Figure Lengend Snippet: Targetable features and therapeutic opportunities in p53abn cancers. A, An upset plot indicating the number of samples with a pathogenic mutation in FBXW7/PPPR1A , ERBB2 amplification or positive HER2 IHC, CCNE1 amplification, HRD (samples with a maximum exposure to Vancouver signature 5 or pathogenic BRCA1 or BRCA2 mutation), and all possible combinations of each. Combinations containing no samples are omitted; all combinations are exclusive such that the number of samples in a combination indicates the number present in those mutation groups and no others. B, Potential targeted therapeutic interventions for the cohort of patients with p53abn endometrial cancer.

Article Snippet: HER2 IHC was performed on whole sections using the 4B5 rabbit monoclonal anti-HER2 Ab from Roche Ventana.

Techniques: Mutagenesis, Amplification